Additional file 1: Figure S1. of Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspensionâ˘ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Chad Orevillo (3584714); Colin Reisner (3584702); Earl St. Rose (3584708); Edward Kerwin (811457); Gary Ferguson (588772); James Pearle (3584705); Leonardo Fabbri (651426); Michael Golden (372987); Patrick Darken (3584720); Roberto Rodriguez-Roisin (3498719); Sanjay Sethi (95853); Sarvajna Dwivedi (3584711); Selwyn Spangenthal (3584723); Tracy Fischer (3584717)

Additional file 1: Figure S1. of Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspensionâ˘ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Authors: Chad Orevillo (3584714)
Colin Reisner (3584702)
Earl St. Rose (3584708)
Edward Kerwin (811457)
Gary Ferguson (588772)
James Pearle (3584705)
Leonardo Fabbri (651426)
Michael Golden (372987)
Patrick Darken (3584720)
Roberto Rodriguez-Roisin (3498719)
Sanjay Sethi (95853)
Sarvajna Dwivedi (3584711)
Selwyn Spangenthal (3584723)
Tracy Fischer (3584717)
Publication date
Publisher
Doi

Abstract

Adjusted change from baseline in FEV1 over time on Day 14 (mITT population). Figure S2. LSM difference in FEV1 AUC0â12 on Day 14, vs placebo MDI (mITT population). (DOCX 437 kb

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/44722...

Last time updated on 12/02/2018